Rapid diagnostic assay for the in-field identification of Coronaviruses including SARS-CoV-2 and detection of mutations in its spike protein from human nasal, buccal or saliva samples. It can be used by individuals without medical expertise to provide integrated sample-to-answer process flow in less than 30 minutes.
Primary Application Area: Healthcare & Medical Devices
Technology Development Status: Prototype
Technology Readiness Level: TRL 6
Organization Type: Mid-stage Startup (A or B)
GOVT/EXTERNAL FUNDING SOURCES